Mesoblast believes that the proposed potency assay measuring remestemcel-L’s in vitro anti-inflammatory and immunomodulatory activity helps establish a clear understanding of remestemcel-L’s ...

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report ...

Sydney, Australia--(Newsfile Corp. - April 29, 2025) - Established gold producer Austral Gold Limited's (ASX: AGD) (TSXV: AGLD) (OTCQB: AGLDF) (Austral or the Company) is pleased to announce that ...

Sydney, Australia--(Newsfile Corp. - January 29, 2025) - Established gold producer Austral Gold Limited (ASX: AGD) (TSXV: AGLD) (OTCQB: AGLDF) (Austral or the Company) is pleased to announce that ...

--Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025 ...

Established gold producer Austral Gold Limited's is pleased to announce that it has filed its Q3 2024 Quarterly Activity Report. Neither TSX Venture Exchange nor its Regulation Services Provider ...

Sydney, Australia--(Newsfile Corp. - January 30, 2024) - Established gold producer Austral Gold Limited (ASX: AGD) (TSXV: AGLD) (OTCQB: AGLDF) (Austral or the Company) is pleased to announce that ...